IVD Medical Buys $19M in ETH to Anchor Tokenization Platform and Treasury Strategy
IVD Medical Holdings, a Hong Kong-listed company, has acquired $19 million (HK$149 million) in ether (ETH), integrating the asset into both its corporate treasury and the infrastructure of its upcoming healthcare tokenization platform, ivd.xyz.
Unlike traditional treasury crypto plays, IVD’s ETH purchase serves a dual purpose: powering the tokenization of real-world assets (RWAs) and generating yield through staking and derivatives strategies. The company aims to tokenize pharmaceutical intellectual property and healthcare-related assets, with Ethereum serving as the foundation for smart contracts, governance, and automated revenue distribution.
The firm is also planning to launch a proprietary stablecoin, IVDD, which will use ETH as its settlement and reserve layer for compliant cross-border payments.
Chief Strategy Officer Gary Deng cited Ethereum’s maturity, deep liquidity, and regulatory clarity — particularly after the U.S. SEC’s spot ETH ETF approval — as key reasons behind the company’s selection of ETH over other crypto assets.
“Ethereum offers the flexibility and security we need to automate complex healthcare asset workflows while maintaining institutional-grade compliance,” Deng said.
The company also announced plans to stake ETH, explore re-staking, and utilize on-chain derivatives to enhance returns and mitigate downside volatility.
IVD’s move places it among a small but growing number of crypto-active firms on the Hong Kong Stock Exchange. Other players include Boyaa Interactive (over 3,100 BTC), Meitu, and Yuxing InfoTech, though most have focused on Bitcoin. IVD stands out with its ETH-first strategy and broader DeFi integration.
The announcement coincides with a newly formalized partnership with HashKey Group, one of Hong Kong’s licensed crypto service providers and operator of the HashKey Exchange.
